Literature DB >> 32804256

What radiologists should know about microRNA (miRNA) serum biomarkers for germ cell tumors.

Matthew A Morgan1, Joanie M Garratt2, David J Vaughn3.   

Abstract

MicroRNAs expressed by germ cell tumors represent a novel approach to detection of metastatic disease during staging, surveillance, and recurrence post-therapy. It has particular promise in settings of equivocal imaging, such as clinical stage I GCT, tumor marker negative stage IIA, or after chemotherapy. These miRNAs have the potential to change typical serum marker evaluation and imaging surveillance schedules.

Entities:  

Keywords:  Germ cell tumor; NSGCT; Seminoma; Testicle; Tumor marker

Mesh：

Substances：

Year:  2020        PMID： 32804256     DOI： 10.1007/s00261-020-02703-3

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  20 in total

1.  ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors.

Authors:  Timothy D Gilligan; Daniel F Hayes; Jerome Seidenfeld; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-07       Impact factor: 3.840

Review 2.  The role of imaging in the diagnosis, staging, and management of testicular cancer.

Authors:  S Aslam Sohaib; Dow-Mu Koh; Janet E Husband
Journal:  AJR Am J Roentgenol       Date:  2008-08       Impact factor: 3.959

Review 3.  Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy.

Authors:  J Baniel; A Sella
Journal:  Semin Surg Oncol       Date:  1999-12

4.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

5.  CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria.

Authors:  S Hilton; H W Herr; J B Teitcher; C B Begg; R A Castéllino
Journal:  AJR Am J Roentgenol       Date:  1997-08       Impact factor: 3.959

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Circulating microRNAs as stable blood-based markers for cancer detection.

Authors:  Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-28       Impact factor: 11.205

Review 8.  Surveillance or Adjuvant Treatment With Chemotherapy or Radiotherapy in Stage I Seminoma: A Systematic Review and Meta-Analysis of 13 Studies.

Authors:  Fausto Petrelli; Andrea Coinu; Mary Cabiddu; Mara Ghilardi; Karen Borgonovo; Veronica Lonati; Sandro Barni
Journal:  Clin Genitourin Cancer       Date:  2015-04-20       Impact factor: 2.872

Review 9.  Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer.

Authors:  Ronak Eini; Lambert C J Dorssers; Leendert H J Looijenga
Journal:  Int J Dev Biol       Date:  2013       Impact factor: 2.203

Review 10.  MicroRNA in prostate, bladder, and kidney cancer: a systematic review.

Authors:  James W F Catto; Antonio Alcaraz; Anders S Bjartell; Ralph De Vere White; Christopher P Evans; Susanne Fussel; Freddie C Hamdy; Olli Kallioniemi; Lourdes Mengual; Thorsten Schlomm; Tapio Visakorpi
Journal:  Eur Urol       Date:  2011-02-01       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.